7-hydroxy-6-methoxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-hydroxy-6-methoxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
• 化学式: C₁₆H₁₈O₁₀
• 分子量: 370.31
• InChiKey: CRSFLLTWRCYNNX-YJDQBUFVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  155
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• COMPOSITION COMPRISING NUTGALL EXTRACT AND FRAXIN AS ACTIVE INGREDIENT FOR IMPROVEMENT OF COGNITIVE ABILITY AND FOR PREVENTION OR TREATMENT OF DEMENTIA AND HYPERACTIVITY DISORDER
  申请人：Kim, Sang Hee

  公开号：EP3900732A1

  公开（公告）日：2021-10-27

  The present invention relates to a composition for improving cognitive ability, and preventing or treating dementia and a hyperactivity disorder, which includes a Galla rhois extract and fraxin as active ingredients. It was identified that the composition including the Galla rhois extract and fraxin significantly improves cognitive memory in an Alzheimer's disease model induced by Aβ (1-42) administration and an APPswe/PS1dE9 double-expressing Alzheimer's disease model, and inhibits the generation of amyloid plaques, suggesting the usefulness of the combination of the Galla rhois extract and fraxin, as a therapeutic material, against Alzheimer's disease, and showing that the combination of the Galla rhois extract and fraxin is able to be used as a therapeutic agent for ADHD

  本发明涉及一种用于改善认知能力、预防或治疗痴呆症和多动症的组合物，其活性成分包括高良姜提取物和fraxin。研究发现，包括高良姜提取物和fraxin的组合物能显著改善Aβ（1-42）给药诱导的阿尔茨海默病模型和APPswe/PS1dE9双表达阿尔茨海默病模型的认知记忆，并抑制淀粉样斑块的生成、表明五倍子提取物和弗莱鑫的组合作为一种治疗材料，对阿尔茨海默病很有用，并表明五倍子提取物和弗莱鑫的组合可用作多动症的治疗剂
• EP3900732A4
  申请人：——

  公开号：EP3900732A4

  公开（公告）日：2022-05-04
• COMPOSITIONS AND METHODS FOR INCREASING PHYTOCHEMICAL BIOAVAILABLITY AND BIOACTIVITY
  申请人：North Carolina State University

  公开号：US20200222474A1

  公开（公告）日：2020-07-16

  The present disclosure relates to the field of microbiota research and therapy. In particular, the present disclosure pro-vides compositions and methods for increasing bioavailability of phytochemicals using probiotic bacteria. Compositions and methods described herein include combinations of probiotic bacteria and prebiotic plant glycosides, wherein the probiotic bacteria are capable of converting the prebiotic plant glycosides into aglycones with increased bioavailability.
• COMPOSITION FOR IMPROVING COGNITIVE ABILITY AND PREVENTING OR TREATING DEMENTIA AND ATTENTION DEFICIT HYPERACTIVITY DISORDER, COMPRISING GALLA RHOIS EXTRACT AND FRAXIN AS ACTIVE INGREDIENTS
  申请人：KIM Sang Hee

  公开号：US20220040240A1

  公开（公告）日：2022-02-10

  The present invention relates to a composition for improving cognitive ability, and preventing or treating dementia and a hyperactivity disorder, which includes a Galla rhois extract and fraxin as active ingredients. It was identified that the composition including the Galla rhois extract and fraxin significantly improves cognitive memory in an Alzheimer's disease model induced by Aβ (1-42) administration and an APPswe/PS1dE9 double-expressing Alzheimer's disease model, and inhibits the generation of amyloid plaques, suggesting the usefulness of the combination of the Galla rhois extract and fraxin, as a therapeutic material, against Alzheimer's disease, and showing that the combination of the Galla rhois extract and fraxin is able to be used as a therapeutic agent for ADHD.
• [EN] COMPOSITION COMPRISING NUTGALL EXTRACT AND FRAXIN AS ACTIVE INGREDIENT FOR IMPROVEMENT OF COGNITIVE ABILITY AND FOR PREVENTION OR TREATMENT OF DEMENTIA AND HYPERACTIVITY DISORDER<br/>[FR] COMPOSITION COMPRENANT UN EXTRAIT DE SUMAC DE CHINE ET UNE FRAXINE EN TANT QUE PRINCIPES ACTIFS POUR L'AMÉLIORATION DE LA CAPACITÉ COGNITIVE ET POUR LA PRÉVENTION OU LE TRAITEMENT DE LA DÉMENCE ET DU TROUBLE D'HYPERACTIVITÉ<br/>[KO] 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물
  申请人：PARK JAMES C

  公开号：WO2020130172A1

  公开（公告）日：2020-06-25

  본 발명은 오배자 추출물 및 프락신을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 또는 치료용 조성물에 관한 것으로, 본 발명에서는 오배자 추출물 및 프락신 조성물은 Aβ (1-42)의 투여로 유도된 알츠하이머 치매 모델 및 APPswe/PS1dE9 이중발현 알츠하이머 치매 모델에서 유의하게 인지기억능을 향상시키고 아밀로이드 플라크의 생성을 억제함을 규명하였고,그러한 결과는 알츠하이머병에 대한 오배자 추출물 및 프락신 조합의 치료 후보물질로서의 유용성을 제시하고, 또한 오배자 추출물 및 프락신의 조합은 ADHD 치료 후보물질로서 이용될 수 있다는 것을 알 수 있다.